NicOx announces positive results from Phase III osteoarthritis study
Naproxcinod 750mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo. Following the positive results from the 301 and 302
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
The allowed claims within this patent application cover compositions of platelet derived growth factor (PDGF) combined with matrix materials having defined characteristics, which cover the company’s recombinant protein-device
SonoSite said that its portable ultrasound products provide point-of-care imaging across multiple clinical applications. Using SonoSite hand-carried ultrasound, the HealthTrust membership will have access at the point-of-care to